Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001140361-25-005025·Arbutus Biopharma Corp
Schedule 13D ownership disclosure
Arbutus Biopharma Corp
Common Shares, without par value · CUSIP: 03879J100
Event date: 2025-02-18
- Filing-level shares
- 38,847,462
- Percent of class
- 20.5%
- Roivant Sciences Ltd.Reported CIK 0001635088
Shares: 38,847,462 · Class: 20.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-25-005025
- Form type
- SCHEDULE 13D/A
- Filer
- Arbutus Biopharma Corp
- CIK
- CIK 1447028
- Filed
- Feb 18, 2025
- Reporting period
- Feb 18, 2025
- Description
- Schedule 13D beneficial ownership